Clicky

Evaxion Biotech A/S(EVAX) News

Date Title
Oct 3 AI from EVAX Improves Trial Results
Oct 3 Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
Sep 26 Evaxion significantly expands vaccine development collaboration with MSD
Sep 26 EVAX Process Continues to Garner Interest and Investment
Aug 29 Evaxion Biotech A/S (NASDAQ:EVAX): Is Breakeven Near?
Aug 8 Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September
Jul 30 EVAX: Initiating Coverage of Evaxion
Jun 26 Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method
Jun 13 Here's Why Evaxion Biotecch (EVAX) Is a Great 'Buy the Bottom' Stock Now
May 28 Evaxion Announces Business Update and First Quarter 2024 Financial Results
May 24 Evaxion Biotech Plans to Unveil 'Positive' Data From Phase 2 Study of Advanced Melanoma Combination Treatment
May 23 Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024
May 10 Evaxion Receives Nasdaq Notification
May 7 Sidoti Events, LLC's Virtual May Micro-Cap Conference
Apr 17 Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
Apr 3 Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
Apr 3 Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript
Apr 2 Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
Mar 27 Evaxion Announces Business Update and Full Year 2023 Financial Results
Mar 22 When Will Evaxion Biotech A/S (NASDAQ:EVAX) Turn A Profit?